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Abstract CCN2 plays a central role in the development and
growth of mesenchymal tissue and promotes the regenera-
tion of bone and cartilage in vivo. Of note, abundant CCN2
is contained in platelets, which is thought to play an
important role in the tissue regeneration process. In this
study, we initially pursued the possible origin of the CCN2
in platelets. First, we examined if the CCN2 in platelets was
produced by megakaryocyte progenitors during differenti-
ation. Unexpectedly, neither megakaryocytic CMK cells
nor megakaryocytes that had differentiated from human
haemopoietic stem cells in culture showed any detectable
CCN2 gene expression or protein production. Together
with the fact that no appreciable CCN2 was detected in
megakaryocytes in vivo, these results suggest that mega-
karyocytes themselves do not produce CCN2. Next, we
suspected that mesenchymal cells situated around mega-
karyocytes in the bone marrow were stimulated by the latter
to produce CCN2, which was then taken up by platelets. To
evaluate this hypothesis, we cultured human chondrocytic
HCS-2/8 cells with medium conditioned by differentiating
megakaryocyte cultures, and then monitored the production
of CCN2 by the cells. As suspected, CCN2 production by
HCS-2/8 was significantly enhanced by the conditioned
medium. We further confirmed that human platelets were
able to absorb/uptake exogenous CCN2 in vitro. These
findings indicate that megakaryocytes secrete some un-
known soluble factor(s) during differentiation, which factor
stimulates the mesenchymal cells to produce CCN2 for
uptake by the platelets. We also consider that, during bone
growth, such thrombopoietic-mesenchymal interaction may
contribute to the hypertrophic chondrocyte-specific accu-
mulation of CCN2 that conducts endochondral ossification.
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Introduction
CCN2/connective tissue growth factor (CTGF), which was
initially regarded as a growth factor, has been now
classified a member of the CCN family of multifunctional
proteins (Lau and Lam 1999; Moussad and Brigstock 2000;
Perbal 2004; Perbal and Takigawa 2005). The CCN family
Concise summary The mechanisms as tohow CCN2 is accumulated in
platelets and how it is abundantly produced by hypertrophic/
prehypertrophic chondrocytes have remained unclear. Here, we describe
an interaction between megakaryocytic and chondrocytic cells, which
may supply CCN2 to both platelets and hypertrophic chondrocytes.
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Cyr61/Cef10/CCN1, Nov/CCN3, rCOP-1/WISP-1/CCN4,
Elm-1/WISP-2/CCN5, and WISP-3/CCN6), each of which
consists of four distinct structural modules, except for
CCN5, which has three modules (Brigstock et al. 2003;
Perbal and Takigawa 2005). CCN2 is known to exert
multiple functions, and to play important roles in cartilage
development and bone formation (Kubota and Takigawa
2007). Under physiological conditions, CCN2 is involved
in embryonic development and differentiation of chondro-
cytes, osteoblasts, and vascular endothelial cells during
endochondral ossification through all stages of this process.
In fact, CCN2 null mice display severe skeletal abnormal-
ities and die soon after birth because of impaired endo-
chondral bone formation (Ivkovic et al. 2003). Under
pathological conditions, CCN2 is associated with fibrosis
(Ahmed and Øie 2007), tumor angiogenesis (Shimo et al.
1999), cell migration (Ono et al. 2008), and the regenera-
tion process of wounded tissues (Nakata et al. 2002;
Kanyama et al. 2003; Shi-Wen et al. 2008). Our recent
reports have revealed that CCN2 was capable of accelerat-
ing harmonized regeneration of defective cartilage and bone
in animal models (Nishida et al. 2004; Kikuchi et al. 2008).
Consistent with its regeneration potential, CCN2 is widely
known to be stored exclusively in normal platelets (Kubota
et al. 2004). Platelets, also referred to as thrombocytes, are
anucleate fragments of megakaryocytes and play a central
role in clotting (Jennings 2009). Platelets are produced by
mature megakaryocytes, which are differentiated from
haemopoietic progenitors in the bone marrow after birth, as
are the other blood cells. These small “cells” without nuclei
contain many bioactive substances involved in cell adhesion
and activation, as well as in coagulation (Kaushansky 2008).
Therefore, platelets play a principal role not only in the
coagulation process but also in wound healing. It should be
noted that, in recent years, platelet-rich plasma (PRP) has
been attracting the attention of clinicians and researchers as
a new approach for connective tissue engineering (Akeda et
al. 2006; Agis et al. 2009; Simman et al. 2008). The
regeneration potential of platelets is due to the inclusion in
them of a number of growth factors, such as platelet-derived
growth factor (PDGF), transforming growth factor (TGF) β1
and 2, and insulin-like growth factor-1 (IGF-1; Weibrich et al.
2002; Cicha et al. 2004; van den Dolder et al. 2006;
Barrientos et al. 2008). Concerning CCN2, previous reports
described that platelets contain much more CCN2 protein
than other normal cells or tissues, indicating its putative role
in the early stage of tissue regeneration (Kubota et al. 2004;
Cicha et al. 2004). In fact, platelets release a vast amount of
CCN2 upon activation. These findings suggest CCN2 to be
an indispensable component of platelets as tissue regenerators
after local injury. However, the origin of CCN2 in platelets is
currently unknown. In other words, how such a secreted
protein with a signal peptide can be stored inside of the
platelets still remains to be clarified.
In this study, we investigated the origin of CCN2
accumulated in platelets, beginning from the analysis of
the platelet producer, i.e., the megakaryocyte. In this
process, quite interesting findings indicating an interaction
between megakaryocytic and chondrocytic cells in the bone
marrow microenvironment were made. Here, we describe a
possible thrombopoietic-mesenchymal interaction that is
crucial for both the formation of platelets and skeletal
development.
Materials and methods
Isolation of haemopoietic stem cells and in vitro
differentiation of megakaryocyte progenitors
Human CD34-positive cells were immunomagnetically
isolated from cord-blood mononuclear cells by an estab-
lished procedure using a MACS CD34 Progenitor Cell
Isolation kit (Miltenyi Biotech). The cord-blood cells were
obtained from Keihan Cord Blood Bank with the approval
of an external ethics committee. In vitro differentiation was
induced by culturing these CD34-positive cells in
RPMI1640 supplemented with 20% human serum (blood
type: AB) and 20 ng/ml of thrombopoietin (Peprotech). At
0, 3, and 10 days after the initiation of the cell cultures, the
cells and conditioned media were separately harvested by
centrifugation. Proper differentiation to the megakaryocytic
lineage was evaluated by a flow cytometer analysis with a
PE-labeled anti-CD41 (Immunotech, BD Bioscience) or
FITC-labeled anti-CD34 monoclonal antibody (Immuno-
tech, Beckmann-Coulter).
Cell lines
Two human cell lines were employed. A human megakar-
yocytic cell line, CMK (Yasui et al. 2005) was maintained
in RPMI1640 containing 10% fetal bovine serum (FBS). A
human chondrocytic cell line, HCS-2/8, was established
from a human chondrosarcoma (Takigawa et al. 1989) and
was cultured in Dulbecco’s modified minimal essential
medium (D-MEM) containing 10% FBS.
RNA extraction and RT-PCR
Total RNA was extracted by the acid-guanidinium phenol-
chloroform method with Trizol reagent, according to the
manufacturer’s protocol. Reverse transcription was carried
out by using avian myeloblastosis virus (AMV) reverse
transcriptase with 200 ng of each total RNA at 42°C for
30 min. Subsequent PCR cycles consisted of an initial
6 K. Sumiyoshi et al.denaturation at94°Cfor 5min and 40cycles of amplification
reaction at 94°C for 20 sec, 51°C for 20 sec and 72°C for
20 sec with Taq polymerase (NEB). PCR products were
analyzed by 1.5% agarose gel electrophoresis and ethidium
bromide staining.
Indirect immunofluorescence analysis of platelets
Human platelets were smeared onto a slice glass and
immediately air-dried. Thereafter, they were fixed in 3.5%
formaldehyde in phosphate-buffered saline (PBS) and
subsequently incubated with a polyclonal antibody against
human CCN2 (anti-CTGFw; Kubota et al. 2004). Immu-
nofluorescence analysis was performed essentially as
described previously (Kubota et al. 2000).
Preparation of platelets and CCN2-absorption analysis
Human platelets were concentrated from human peripheral
blood from 2 healthy volunteers. Initially, leukocytes and
erythrocytes were removed by centrifugation at ×130 g for
15 min. Thereafter, the platelets were concentrated by
another centrifugation at ×900 g for 10 min. The resultant
plasma contained 4×10
5 platelets/µl. The platelets (2×10
7)
were then exposed to 200 ng/ml of recombinant CCN2 in
100 µl of 50% plasma in Dulbecco’s phosphate-buffered
saline (PBS) for the desired time periods. Immediately after
the addition of 1 ml of PBS for wash, the platelets were
pelleted by centrifugation at ×2,000 g for 7 min and lysed
in 50 µl of a 1 × sodium dodecyl-sulfate (SDS) sample
buffer containing 2-mercaptoethanol. Equal volumes of
each sample were subjected to SDS-polyacrylamide gel
electrophoresis (PAGE) and Western blotting analysis.
CCN2 induction assay with HCS-2/8 cells
HCS-2/8 cells were utilized to estimate the effect of soluble
factors in medium conditioned by megakaryocyte progen-
itors on the CCN2 production by the mesenchymal cells.
The mesenchymal HCS-2/8cells were grown in D-MEM
supplemented with 10% FBS and seeded at a cell density of
5×10
5/35-mm in tissue culture dishes. Thereafter, serum-
free D-MEM mixed with a quarter volume of each
conditioned medium from megakaryocyte in vitro differen-
tiation cultures was added to replace the growth medium.
Twelve hours after the medium change, the culture
supernatant was collected and subjected to ELISA for the
quantification of CCN2 secreted from the HCS-2/8 cells.
CMK-HCS-2/8 co-culture analysis
HCS-2/8 cells were seeded at a density of 5×10
5 cells per
well in a 6-well cell culture plate and cultured overnight.
Thereafter, CMK cells (1.5×10
6) in RPMI1640 containing
10% FBS were added to replace the tissue culture medium.
After 0, 6, and 24 h, the tissue culture supernatant and
floating cells were separately recollected by centrifuga-
tioon. More than 90% of the recollected cells were
confirmed to be CD41
+ via FACS analysis. CMK cell
lysates were prepared by adding 1×10
6 CMK cells to 1 ml
of RIPA buffer (50 mM Tris-HCl, pH 8.0, containing
150 mM NaCl, 1% NP-40, 0.5% deoxycholate, and 0.1%
SDS). CCN2 in the tissue culture supernatant and cell
lysate was quantified by ELISA.
Western blotting analysis
SDS-PAGE and Western transfer of proteins were per-
formed as described previously (Kubota et al. 2004).
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Fig. 1 a Threepossible pathways to supplyCCN2toplatelets.I:CD41
+
megakaryocyte progenitor cells produce CCN2, which is then taken up
by the platelets. II: Megakaryocytes themselves produce CCN2 that is
directly encapsulated upon platelet formation. III: CCN2 is produced by
the cells of another lineage, such as mesenchymal cells, in the same
microenvironment and is taken up by platelets. Abbreviations: Meg
megakaryocyte; Pt platelet. b No CCN2 production from the human
megakaryocytic cell line CMK. CD41
+ CMK cells were cultured for
7 days without changing the medium, and CCN2 protein in the culture
supernatant was analyzed by ELISA. As a positive control, the CCN2
concentration in the culture supernatant of HCS-2/8 cells stimulated
with 2.5% FBS for 12 h is presented. The dotted line indicates the
background level obtained with the medium only (18.2 ng/ml). Data
were obtained from 2 independent sets of samples
Thrombopoietic-mesenchymal interaction and CCN2 7Briefly, proteins in 20 µl of platelet lysate described in a
previous subsection were separated by SDS-PAGE (in a
12% acrylamide gel), and transferred onto a polyvinylidene
difluoride (PVDF) membrane (Amersham Bioscience).
After having been blocked with 5% skim milk in Tris-
buffered saline (TBS), the membrane was incubated at 4°C
for 24 h with 1:350-fold-diluted mouse monoclonal
antibody against CCN2 von Willebrand factor type C
repeat (VWC) module (Minato et al. 2004) or 1:1,000-fold
diluted mouse monoclonal anti-actin antibody (SIGMA St.
Louis, MO, USA). After extensive washes, it was then
incubated with 1:5,000-fold diluted anti-mouse IgG horse-
radish peroxidase (HRP) conjugate (GE Healthcare). The
blot was visualized by use of an enhanced chemilumines-
cence (ECL) analysis system (GE Healthcare).
Enzyme-linked immunosorbent assay (ELISA)
CCN2 was quantified by using a sandwich ELISA system
with two anti-human CCN2 monoclonal antibodies (MAb
8-64 and 8-86; mouse IgG1) provided by Nichirei Corp.
(Tokyo, Japan), as described previously (Kubota et al.
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Fig. 2 Analysis of CCN2 gene
expression and protein
production during the course of
megakaryocytic differentiation.
Human cord blood CD34
+ cells
were caused by thrombopoietin
to differentiate in vitro toward
the megakaryocyte lineage. The
cells were sampled at the
indicated time points and then
analyzed by FACS for cell
morphology and demonstration
of cell-surface antigens (a), by
RT-PCR for CCN2 expression
(b), and by ELISA for CCN2
production (c). Abbreviations
SSC, FSC, PE, and FITC in
panel A denote side scatter,
forward scatter, propidium
iodide, and fluorescein
isothiocyanate, respectively.
Total RNA from HCS-2/8 cells
was utilized as a positive control
in panel b. Similar experiments
with peripheral blood-derived
haemopoietic stem cells yielded
comparable results (data not
shown)
8 K. Sumiyoshi et al.2004). In brief, samples were applied to ELISA strips
coated with MAb 8-64 and incubated for 2 h. After six
cycles of washing, horseradish peroxidase-conjugated MAb
8-86 was added, and the strips were incubated for 1 h. The
signals were developed via an enzymatic reaction with
tetramethylbenzidine.
Immunohistochemistry
Immunohistochemical staining was performed as described
previously (Moritani et al. 2003). Briefly, paraffin-
embedded sections from 6-week-old mice were deparaffi-
nized, blocked and incubated with an anti-CCN2 serum
reactive with murine CCN2 at a dilution of 1: 200. After the
reaction with horseradish peroxidase-conjugated secondary
antibody, the signals were developed by use of 3′-
diaminobenzidine. Finally, the samples were counterstained
with hematoxylin.
Results
Evaluation of the CCN2 gene expression and protein
production by megakaryocytic CMK cells
Since platelets are directly produced by megakaryocytes,
we first suspected megakaryocytes as the source of CCN2
encapsulated in platelets (Fig. 1a). As an initial step, we
employed the CMK cell line, a human cell line retaining the
megakaryocytic phenotype, such as CD41 expression, for
the evaluation of CCN production. However, neither CCN2
mRNA expression (data not shown) nor CCN2 production/
secretion (Fig. 1b) was detectable under regular cell culture
conditions.
Evaluation of the CCN2 gene expression and protein
production by differentiating megakaryocytic progenitors
in vitro
Since CMK is an established immortal cell line, it may not
precisely retain the complete megakaryocytic phenotype.
Therefore, we subsequently isolated CD34-positive haemo-
poietic stem cells from human cord blood leukocytes by
cell sorting; and cytodifferentiation towards megakaryocyte
progenitors was induced by incubation with recombinant
thrombopoietin. According to the result of flow cytometric
analysis, those cells initially showed morphological
changes such as increased cell size, which was represented
by the forward scatter values, 3 days after initiating the
induction of differentiation. Thereafter, demonstration of
CD41 molecules was clearly observed 10 days after the
start of the cell cultures (Fig. 2a). These findings indicate
that the isolated cells were mostly composed of haemopoietic
stem cells that could differentiate into megakaryocyte pro-
genitors in vitro. Under the same culture conditions, total
RNA was isolated and subjected to PCR analysis for the
detection of CCN2 mRNA. However, no CCN2 mRNA was
detectable in the cells in the differentiating cultures at either
0, 3 or 10 days after the beginning of the cultures; whereas
β-actin mRNA was definitely detected at all times (Fig. 2b).
Consistent with this result, no CCN2 protein was detected in
the cell culture supernatant, either (Fig. 2c). Therefore, we
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Fig. 3 Promotion of CCN2 production from chondrocytic HCS-2/
8 cells by a soluble factor produced by megakaryocyte progenitors. a
Experimental strategy. The conditioned medium was sampled at days
0, 3, and 10 from human CD34-positive cell cultures differentiating
toward megakaryocytes. HCS-2/8 cells were maintained in the
presence of each conditioned medium (20% in serum free D-MEM)
for 12 h, and the cell culture supernatant was then subjected to ELISA
for the quantification of the secreted CCN2. b Production of CCN2
from HCS-2/8 cells stimulated by the culture supernatants. The data
show the concentration of CCN2 accumulated in the HCS2/8 cell
culture supernatant during 12 h after adding the conditioned medium
from the megakaryocyte progenitor cultures. Experiments were
repeated twice, and comparable results were obtained
Thrombopoietic-mesenchymal interaction and CCN2 9concluded that, during the differentiation in vitro,C C N 2w a s
not produced by megakaryocyte progenitors. In addition,
since terminal differentiation to mature megakaryocytes
producing platelets was not inducible in vitro,w ep e r f o r m e d
immunohistochemical staining to detect CCN2 in mature
megakaryocytes in mouse bone marrow. Consequently, we
could detect no positive signal representing CCN2 produc-
tion (data not shown; Cicha et al. 2004).
Effect of the culture medium conditioned by differentiating
megakaryocyte progenitors on the CCN2 production
by mesenchymal cells
Platelets are known to take up a variety of molecules via
endocytosis. Therefore, we addressed the possibility that
megakaryocyte progenitors may force other cells in the
same microenvironment to secrete CCN2, which is subse-
quently taken up and accumulated in the nascent platelets.
Megakaryocytes mature in the bone marrow, in which a
wide variety of mesenchymal cells reside together with the
haemopoietic cells. Among these mesenchymal cells,
growth plate chondrocytes facing the bone marrow are
known to produce a vast amount of CCN2 in vivo; whereas
other types of mesenchymal cells, such as osteoblasts and
mesenchymal stem cells, produce only limited amounts. In
order to examine if megakaryocytes contribute to the
induction of CCN2 production by chondrocytes, we
evaluated the effect of the conditioned medium from
megakaryocyte cultures on the production of CCN2 by
chondrocytic cells (Fig. 3a). HCS-2/8 cells, which were
known to retain the chondrocytic phenotype, were
employed. As a result, the amount of CCN2 secreted by
HCS-2/8 cells was remarkably increased by the addition of
the conditioned medium from differentiating megakaryo-
cyte cultures taken at day 3 (Fig. 3b). These data indicate
that megakaryocyte progenitors produce some unknown
soluble factor(s) that targets surrounding mesenchymal
cells, including prehypertrophic/hypertrophic chondrocytes,
and forces them to produce CCN2.
Effect of the culture medium conditioned by CMK cells
on the CCN2 production by mesenchymal cells
According to the results shown in Fig. 3, the ability of
differentiating megakaryocyte progenitors to stimulate
CCN2 production from HCS-2/8 cells diminished at a later
stage of differentiation. In order to further confirm this
finding, we evaluated the corresponding ability of CMK
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Fig. 4 No effect of the
conditioned medium from CMK
cells on the CCN2 production
from HCS-2/8 cells. a CMK
cells show the phenotype of
megakaryocyte progenitors at a
late differentiation stage. The
presence of CD41 (abscissa) and
CD34 (ordinate) on CMK cells
was examined, with the results
plotted in a 2-dimensional
representation. Isotype control is
also shown. The percentage of
each population is indicated in
each section as well. b Effect of
the conditioned medium from
CMK cells maintained for
3 days on the CCN2 production
from HCS-2/8 cells. The
relatively high background (day
0) may be ascribed to the
involvement of 10% FBS in the
conditioned medium
10 K. Sumiyoshi et al.cells. As shown in Fig. 4a, CMK cells were confirmed to
retain the phenotype of megakaryocyte progenitors at a late
stage of differentiation, as represented by a high level of
CD41 without CD34. As expected, the result of the CCN2
induction assay revealed no enhancement of CCN2 pro-
duction from HCS-2/8 cells by the CMK conditioned
medium (Fig. 4b). Therefore, these data indicate that the
factor stimulating CCN2 production was released predom-
inantly by the megakaryocyte progenitors at relatively early
stages of differentiation.
Localization of CCN2 in platelets
Although the inclusion of CCN2 in platelets has been
clearly demonstrated, its subcellular localization therein has
not been analyzed. Thus, we carried out immunofluores-
cence analysis to investigate the mode of CCN2 distribution
in platelets. As a result, CCN2 was not distributed evenly in
the cytoplasm, but had accumulated in granular structures
(Fig. 5a).
Absorption/uptake of extracellular CCN2 by platelets
The fact that CCN2 was found in platelet granules suggests
that CCN2 might have been endosomally acquired and
accumulated in the granules until released. Thus, we next
tested to see if normal platelets with CCN2 were still capable
of taking up extracellular CCN2. Platelets were concentrated
from human blood, and CCN2 was exogenously added to the
platelet suspension. Thereafter, the platelets were collected;
and the platelet-associated CCN2 was then detected by
Western blotting. After the addition of the exogenous CCN2
to platelets, the quantity of CCN2 associated with platelets
increasedwithtime(Fig.5b). Although it is not clear whether
the platelets had incorporated the CCN2 by endocytosis or
had simply adsorbed it, the observed continuous increase in
CCN2 up to 40 min may represent intracellular uptake of
CCN2 by platelets. It should be noted here that a number of
proteins have been shown to be taken up by endocytosis into
platelets (Escolar et al. 2008).
No significant transfer of CCN2 from mesenchymal
HCS-2/8 cells to CD41-positive CMK cells
In addition to the direct uptake by platelets, another
possible pathway to package exogenous CCN2 in platelets
is the endocytotic incorporation by megakaryocytic pro-
genitors. To evaluate this possibility, we co-cultured CMK
cells with HCS-2/8 cells (Fig. 6a), and then quantitatively
analyzed CCN2 in CMK cells after conducting a time-
course experiment. However, although CCN2 is efficiently
produced by HCS-2/8 cells, no incorporation of CCN2 by
CMK cells was observed (Fig. 6b). Therefore, transfer of
CCN2 from mesenchymal cells to megakaryocytic progen-
itors cells may not occur, even under the direct cell-to-cell
contact between them.
Abundant CCN2 found in hypertrophic chondrocytes
It is known that CCN2 is mainly produced by hypertrophic
chondrocytes facing, or adjacent to bone marrow in the
growth plate (Takigawa et al. 2003), which is consistent
with our present findings. To confirm this point, we
reevaluated the distribution of CCN2 in the mouse growth
plate and found that CCN2 was abundantly produced by
late hypertrophic chondrocytes near the bone marrow,
whereas a relatively limited amount was detected in the
inner side (Fig. 7a). These results suggest a possible
haemopoietic-mesenchymal interaction that enables the
enhanced CCN2 production by hypertrophic chondrocytes.
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Fig. 5 a Distribution of CCN2 in platelets. CCN2 in human platelets
was visualized by immunofluorescence analysis and was viewed at a
magnification of ×400. CCN2 is found in granular structures therein. b
Absorption/incorporation of exogenous CCN2 to/by human platelets.
After the addition of CCN2, human platelets were collected and
subjected to Western blotting for the detection of CCN2. Western
blotting against actin was also performed as an internal control. The
intensity of the signals at 38 kDa, representing full-length CCN2,
increased with time up to 40 min after the addition of CCN2. The
minor bands are anticipated to be proteolytic N-terminal fragment of
CCN2. Evaluation was performed with two samples from independent
donors, and similar results were obtained
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In the present study, we first pursued the origin of CCN2 in
platelets. Initially we suspected megakaryocytes to be the
direct source; however, we consequently detected no CCN2
mRNA or protein in megakaryocytes or in their progeni-
tors, including the CMK cell line. Next, we investigated the
mesenchymal cells around platelets to examine if CCN2
could be supplied by those cells following interaction with
megakaryocyte progenitors. As a result, we uncovered a
quite interesting interaction between megakaryocyte pro-
genitors and mesenchymal cells in vitro. Recently, the
importance of interactions between haemopoietic and
mesenchymal cells has been widely recognized. Indeed,
the regulation of self-renewal and differentiation of haemo-
poietic stem cells (HSC) requires a specific microenviron-
ment of surrounding cells known as the niche, in which
osteoblasts and HSCs tightly interact via angiopoietin-1 and
Tie-2 (Arai et al. 2004; Calvi et al. 2003). It is widely
known that megakaryocyte progenitors do not undergo final
maturation to produce platelets in vitro. Therefore, mega-
karyocytes also need a certain interaction(s) with non-
haemopoietic cells, including mesenchymal cells, in order
to mature and produce functional platelets. Here, we found
one such interaction between megakaryocytes and mesen-
chymal cells (Fig. 5), which supplies CCN2 to platelets to
accomplish their maturation, since CCN2 is an important
component of platelets for their tissue-repair function. The
cell-surface molecules that mediate the incorporation of
CCN2 into platelets are unclear. However, one of the CCN2
receptors, low-density lipoprotein receptor-related protein 1
(LRP1), is known to function as an endocytotic receptor
(Kawata et al. 2006). Moreover, direct interaction of CCN2
with integrin αIIbβ3, which was shown to mediate
endocytosis of fibrinogen into platelets (Handagama et al.
1993; Jedsadayanmata et al. 1999), is clearly a possibility.
a
CMK CMK
HCS 2/8
CCN2 ?
HCS-2/8
b
CMK
120
140
100
120
m
l
)
60
80
2
 
(
n
g
/
m
40
60
C
C
N
2
20
40
C
0
   0  h 6  h 2  4  h
   0  h 6  h 2  4  h
Medium
120
140
100
120
m
l
)
80
(
n
g
/
m
40
60
C
N
2
 
20
40
C
0
Fig. 6 Evaluation of the intercellular transfer of CCN2 from HCS-2/8
to CMK cells. a Experimental strategy. CMK cells were seeded onto
HCS-2/8 cells that had been attached to tissue culture wells and allowed
to make cell-to-cell contact. b No transfer of CCN2 into CMK cells.
After the indicated intervals, CCN2 in CMK cell lysates and co-culture
media was quantified by ELISA
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Fig. 7 a Immunostaining of CCN2 produced by chondrocytes in the
hypertrophic layer of mouse growth plate near the bone marrow. Note
that cells on the bone marrow side accumulate more CCN2 than those
on the inner side. b Schematic representation of possible
thrombopoietic-mesenchymal interaction around the growth plate-
bone marrow boundary. We hypothesize that megakaryocyte progen-
itors secrete some unknown soluble factor during differentiation,
which factor stimulates the chondrocytes facing the bone marrow to
produce CCN2. During bone growth, this interaction contributes to the
accumulation of CCN2, not only in platelets, but also in the
hypertrophic chondrocytes that conduct proper endochondral ossifi-
cation. Abbreviations: R resting chondrocyte; G growing chondrocyte;
Pre-H pre-hypertrophic chondrocyte; H hypertrophic chondrocyte;
Meg megakaryocyte
12 K. Sumiyoshi et al.Investigation of the interaction of CCN2 with these
molecules will eventually clarify if/how CCN2 is incorpo-
rated by endocytosis.
The role of CCN2 in wound healing and tissue
regeneration has been widely recognized. The CCN2
gene is expressed in the process of tissue regeneration
that occurs in the wound healing process and bone
fracture repair. Furthermore, the utility of CCN2 in tissue
regenerative therapeutics has been established. Recently
in many fields, the clinical application of platelet-rich
plasma (PRP) has been frequently reported; and PRP has
significant effects on soft and hard tissue regeneration,
which are comparable to the effect of cytokine treatment
(Mirabet et al. 2008;S i m m a ne ta l .2008). Additionally, it
should be noted that PRP is quite safe and is relatively not
expensive. Obviously, CCN2 abundantly included in
platelets may contribute to the regeneration potential of
platelets. As such, proper encapsulation of CCN2 is a
critical step for platelets to be fully functional as a key
player in wound healing.
In the growth plate, CCN2 is abundantly produced by a
limited population of chondrocytes facing the bone marrow,
which cells are called hypertrophic/prehypertrophic chon-
drocytes. This specific CCN2 production in hypertrophic/
prehypertrophic chondrocytes is widely known and is
necessary for the proper endochondral ossification leading
to the normal growth of long bones (Fig. 7a; Kubota and
Takigawa 2007). Nevertheless, the mechanism as to how the
production of CCN2 isstrongly induced only in hypertrophic/
prehypertrophic chondrocytes around the bone marrow is still
unclear. In this context, our present data suggest for the first
time the involvement of thrombopoietic-mesenchymal inter-
action in the mechanism that causes hypertrophic/prehyper-
trophic chondrocyte-specific accumulation of CCN2 to
conduct endochondral ossification. Thus, this haemopoietic-
mesenchymal cell interaction may be critical not only for
platelet maturation but also in the endochondral ossification
process (Fig. 7b).
However, a number of issues still remain to be
investigated. First of all, the soluble factor that is produced
by megakaryocytic progenitors and induces CCN2 produc-
tion has not been specified yet. We initially suspected TGF-
β as such a molecule and tried to detect TGF-β mRNA in
megakaryocyte progenitors, because this factor is known to
p r o m o t eC C N 2p r o d u c t i o ni nav a r i e t yo ft h ec e l l s .
However, neither mRNA for TGF-β1 nor TGF-β2 was
detected (data not shown). As a second issue, chondrocytes
are available during the growth period as suppliers of
CCN2. Then, after the closure of the growth plate, which
mesenchymal cells would produce CCN2 for platelets? One
such candidate is the mesenchymal stromal cell, but no data
to support this hypothesis are available yet. So far as
platelets are produced through the life, some other major
CCN2 producer(s) than the hypertrophic chondrocytes must
be found in adult bone marrow. Identification of the soluble
factor that provokes CCN2 production and evaluation of
the responsiveness to this factor by other types of
mesenchymal cells are currently underway.
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